ALMSHealthcare · BiotechnologyThe 10 Wall Street analysts covering Alumis, Inc. hold a median 12-month price target of $32 — +248.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 10 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Alumis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (29): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALMS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +248.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Sept 2026 | Guggenheim | Downgrade | Neutral | — |
| 2 Sept 2026 | HC Wainwright & Co. | Upgrade | Buy | $25 → $15 |
| 2 Sept 2026 | Morgan Stanley | Maintains | Overweight | $39 → $29 |
| 2 Sept 2026 | Oppenheimer | Maintains | Outperform | $55 → $37 |
| 2 Sept 2026 | Wells Fargo | Maintains | Overweight | $51 → $25 |
| 14 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 14 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | $25 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | $25 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 19 May 2026 | Chardan Capital | Maintains | Buy | $38 → $40 |
| 19 May 2026 | Chardan Capital | Maintains | Buy | — |
| 15 May 2026 | Guggenheim | Maintains | Buy | $32 → $34 |
| 15 May 2026 | Guggenheim | Maintains | Buy | — |
| 15 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | $25 |
| 15 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 15 May 2026 | Wells Fargo | Maintains | Overweight | $49 → $51 |
| 30 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 30 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Alumis, Inc. returned +110.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 3% of US stocks
Cheaper than 34% of US stocks
Cheaper than 72% of US stocks
Higher than 7% of US stocks
Higher than 13% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 14% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alumis, Inc. has a market value of $1.2B and an enterprise value of $815.5M.
Revenue in the twelve months to 30 June 2026: $7.4M. The latest quarter shrank 37.7% year on year.
Net income over the same four quarters: −$439.0M, a −5933.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$351.8M.
Trailing P/E: 0.2×; forward P/E: −3.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Alumis, Inc. employs 237 people — $31K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alumis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alumis Inc., a late-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases, announced on September 4, 2026, that it will participate in upcoming investor conferences in September.
Why it matters — Investors watching ALMS may gain insight into the company's progress and strategy through its presentations at upcoming investor conferences.
Seeking Alpha reports that Alumis Inc. is a late-stage biotech with no commercial product whose value rests primarily on envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. A recent lupus trial failure caused a significant share price crash, though the report suggests this may not erase the drug's psoriasis potential.
Why it matters — ALMS watchers would care because the lupus trial failure is a major setback to the company's primary pipeline asset, although its psoriasis program may still support some upside.
Alumis, Inc. shares fell after the California-based biotech reported that envudeucitinib failed to meet the primary endpoint of a mid-stage lupus trial. The drug's failure in this trial drove a 58% decline in the company's stock.
Why it matters — The failure of envudeucitinib in a mid-stage lupus trial raises significant questions about the prospects of one of Alumis's key pipeline candidates.
Alumis Inc. issued a transcript discussing the Phase IIb LUMUS trial results and subgroup insights related to type 1 interferon-driven diseases. The transcript covers the company's presentation of these clinical findings.
Why it matters — ALMS watchers would care because the LUMUS Phase IIb trial data is central to the company's clinical progress in type 1 interferon-driven diseases.
Alumis reported that its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet its primary or key secondary endpoints in the overall study population. However, pre-specified analyses showed clinically meaningful responses among patients with a high interferon gene signature, a subgroup the company plans to emphasize in future regulator discussions.
Why it matters — ALMS watchers would care because the trial missed its main goals, raising questions about the drug's broader prospects, while a promising high-interferon subgroup may shape the company's future development path.
The 10 Wall Street analysts covering Alumis, Inc. have a median 12-month price target of $32, with estimates ranging from $15 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Alumis, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alumis, Inc. 43 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, Alumis, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +248.8% from the last close, and Ticker Nerd's factor model ranks Alumis, Inc. 43 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alumis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $46 over the next 12 months.
Alumis, Inc. returned +110.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases.
The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Alumis to Participate in Upcoming September Investor Conferences". Alumis Inc., a late-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases, announced on September 4, 2026, that it will participate in upcoming investor conferences in September.
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company’s current pipeline centers on oral TYK2 inhibitors designed to address conditions such as plaque psoriasis and systemic lupus erythematosus, alongside a CNS-penetrant TYK2 program being studied for neuroinflammatory and neurodegenerative disorders. Alumis is also advancing lonigutamab, an antibody therapy aimed at thyroid eye disease, and additional discovery-stage programs built around its precision data analytics platform. The company works across immunology and inflammation, combining drug discovery, clinical development, and translational science to build treatments that may be used as monotherapy or in combination settings. Headquartered in South San Francisco, California, Alumis operates as a focused biotech platform in the autoimmune and immune dysfunction market.
CEO Mr. Martin Babler Ph.D. · 237 employees · United States · https://www.alumis.com
